Video Interview: Enumeral Aspires To Take PD-1 Inhibition To Next Level
This article was originally published in Scrip
Executive Summary
Enumeral CEO Arthur Tinkelenberg explains his company's human-driven immune profiling platform and how it could help develop tomorrow's checkpoint inhibitors to Emily Hayes, senior writer for Scrip's sister publication "The Pink Sheet."